- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Europe Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Forecast to 2031
USD 7.78 BN
MARKET SIZE, 2031
CAGR 10.0%
(2026-2031)
200
REPORT PAGES
150
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe digital diabetes management market, valued at USD 6.89 billion in 2025, stood at USD 7.78 billion in 2026 and is projected to advance at a resilient CAGR of 10.0% from 2026 to 2031, culminating in a forecasted valuation of USD 12.53 billion by the end of the period. The rapid uptake of continuous glucose monitoring systems, smart insulin pens, and connected glucometers across Europe is a significant enabler of digital diabetes management. These devices generate continuous, real-time data that can be integrated into digital platforms for monitoring, alerts, and personalized insights.
KEY TAKEAWAYS
-
BY REGION
Germany is expected to register the highest CAGR of 11.9% during the forecast period.
-
BY PRODUCTS & SERVICES
By product & service, the devices segment dominated the market, with a share of 74.5% in 2025.
-
BY DEVICE TYPE
By device type, the wearable devices segment dominated the market, accounting for a 46.5% share in 2025.
-
BY END USER
By end user, the self/home healthcare segment is expected to be the fastest-growing segment during the forecast period.
-
COMPETITIVE LANDSCAPE - Key Players
Medtronic (Ireland), Dexcom, Inc. (US), and Abott (US) were identified as Star players in the Europe digital diabetes management market, as they have focused on innovation and have broad industry coverage and strong operational and financial strength.
-
COMPETITIVE LANDSCAPE - Start Ups
Spike (Sweden), Noom (Ukraine), and PKvitality (US) distinguished themselves among startups and SMEs due to their strong product portfolio and business strategy.
European Union initiatives promoting digital health transformation play a critical role in market growth. Programs aimed at improving interoperability, electronic health records, and cross-border health data exchange encourage the adoption of digital disease management solutions. The European Health Data Space initiative, in particular, is expected to enhance secure data access and secondary use of health data for research and innovation. These policy-level efforts enhance the digital infrastructure required for diabetes platforms to scale across countries, while supporting outcomes tracking and the generation of real-world evidence.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
There is significant evolution in the Europe digital diabetes management market driven by the increasing prevalence of diabetes and a gradual shift towards continuous, remote patient monitoring in key countries such as Germany, the UK, and France. Such priorities from healthcare providers include effective and efficient digital platforms able to deliver glycemic results at affordable public health budget costs. The rise of CGM systems, AI-based analytics, and mHealth applications resulted in their consequent influence on changing care pathways. Simultaneously, the competitive landscape is shifting due to data privacy regulations, differences in reimbursement, and integration of early hospital IT systems. At the same time, further telehealth infrastructures and value-based care models keep encouraging demand for new digital diabetes solutions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Rising Prevalence of Diabetes
-
Advancements in Digital Health Technologies
RESTRAINTS
Impact
Level
-
High Costs and Uneven Reimbursement
-
Data Privacy and Security Concerns
OPPORTUNITIES
Impact
Level
-
Integration of AI and Predictive Analytics
-
Mobile Health Apps and Telehealth Expansion
CHALLENGES
Impact
Level
-
Healthcare System Fragmentation and Interoperability
-
Regulatory Complexities and Time-to-Market Delays
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Europe has a large and growing diabetic population—estimated at over 60 million people—driven by aging demographics, rising obesity, and lifestyle shifts. This epidemiological burden is increasing demand for digital tools that help manage glucose levels, improve clinical outcomes, prevent complications, and reduce long-term healthcare costs. Higher disease prevalence motivates healthcare systems and patients alike to adopt digital diabetes solutions like CGM, data-driven apps, and connected platforms, thereby sustaining market growth across both consumer and clinical segments.
Advanced digital diabetes management systems, especially continuous glucose monitoring (CGM) and AI-integrated platforms, carry relatively high upfront and recurring costs. While robust healthcare systems in Western Europe may cover some costs, reimbursement coverage remains inconsistent across countries, particularly in Eastern Europe. High device and platform costs can deter adoption among price-sensitive patients, constrain uptake in underfunded regions, and limit market penetration, thereby slowing growth despite strong clinical demand.
Artificial intelligence and machine learning are reshaping diabetes care by enabling predictive glucose trend analysis, personalized treatment recommendations, and automated decision support. AI-driven insights can optimize patient outcomes, reduce complications, and support clinicians with actionable analytics. As healthcare systems increasingly emphasize value-based care, AI offers opportunities for providers to differentiate solution offerings, increase engagement, and deliver scalable services that go beyond basic monitoring.
Europe’s diverse healthcare landscape, with varying reimbursement policies, regulatory frameworks, and EHR systems, presents interoperability challenges. The lack of standard data formats and protocols can impede the seamless integration of digital diabetes tools with existing clinical workflows, reducing efficiency and limiting the value of unified care management solutions. Addressing cross-system compatibility is critical for broader adoption.
EUROPE DIGITAL DIABETES MANAGEMENT MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Integrated digital diabetes management ecosystem combining insulin pumps, CGM systems, and data-driven software platforms, widely adopted across European hospitals and specialty clinics for intensive diabetes management | Improved glycemic control and workflow integration| Strong clinical evidence |
|
|
Advanced real-time CGM solutions designed for continuous remote monitoring and smartphone-based diabetes management, increasingly used in homecare and telehealth settings across Europe | High data accuracy| Real-time insights| Enhanced patient engagement |
|
|
Flash and continuous glucose monitoring systems supported by intuitive mobile apps and cloud connectivity, enabling large-scale adoption in cost-sensitive European public healthcare systems | Ease of use| Reduced finger pricks| Broad reimbursement coverage |
|
|
Digital diabetes platforms integrated with blood glucose monitoring devices, offering data analytics and decision-support tools for patients and healthcare professionals in Europe | Reliable data management and clinical decision support| Strong brand trust |
|
|
Connected blood glucose monitoring solutions and digital apps tailored for self-management and outpatient diabetes care across European markets | Cost-effective monitoring| Patient-friendly interfaces| Strong regional presence |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Europe digital diabetes management market ecosystem comprises leading multinational players such as Medtronic, Abbott, Dexcom, F. Hoffmann-La Roche, and Ascensia Diabetes Care, which drive innovation across connected glucose monitoring, insulin delivery systems, and digital care platforms. These companies develop integrated solutions combining hardware, mobile applications, cloud analytics, and remote monitoring tools to support continuous diabetes management. Supporting this ecosystem are software developers, cloud service providers, sensor and semiconductor suppliers, and data analytics firms, which enable device connectivity and real-time insights. The end users include public and private hospitals, diabetes clinics, primary care providers, and home care settings across countries such as Germany, the UK, France, Italy, and Spain. This interconnected ecosystem enhances care coordination, supports value-based healthcare models, and accelerates the adoption of digital diabetes solutions across Europe.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
In 2025, the CGM segment held the largest market share for digital diabetes management. CGM market dominance enables players to broaden applications beyond traditional Type 1 diabetes users. By targeting insulin-dependent Type 2 diabetes patients, gestational diabetes cases, and high-risk prediabetic populations, companies can unlock new growth avenues. Strong clinical evidence, supported by large installed user bases, helps justify expanded reimbursement and physician adoption, significantly increasing patient penetration across Europe.
Both handheld and wearable devices are the sub-segment of the device types that are taken into account in the digital diabetes management device market. In 2025, wearable technology accounted for largest share of the market for digital diabetes management devices. During the forecast period, this segment is anticipated to grow at the highest CAGR. The market for wearables is growing as a result of technological advancements, an increase in the adoption of smart insulin pumps and insulin patches, and an increase in the number of regulatory approvals for wearables.
In 2025, the self-/home healthcare segment held the largest market share for digital diabetes management. This is primarily attributed to the rising patient acceptance of home care as a result of growing awareness of digital platforms for managing diabetes. Patients who require continuous insulin therapy benefit most from self-administration. Inpatient treatment is very expensive for patients who require long-term therapy, and it also keeps them from going back to their daily routines.
REGION
Germany to be fastest-growing region in Europe digital diabetes management market during forecast period
The German healthcare system is very well developed and integrated between primary care, specialists, and hospitals. Physicians become increasingly ready to prescribe and monitor digital diabetes solutions alongside conventional therapies. Strong clinical workflows with data standards and general acceptance of eHealth facilitate the seamless integration of digital tools that can easily and sustainably be used throughout the country in diabetes management.
EUROPE DIGITAL DIABETES MANAGEMENT MARKET: COMPANY EVALUATION MATRIX
In the Europe digital diabetes management market, Dexcom (Star) has a strong and established product portfolio and a vast geographic presence. AgaMatrix (Emerging Leader) has substantial product innovations compared to its competitors. While they have broad product portfolios, they lack a strong growth strategy for business development, particularly in terms of geographic expansion, strategic partnerships, and aggressive commercialization initiatives compared to leading players in the market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Medtronic (Ireland)
- Dexcom, Inc. (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Ascensia Diabetes Care Holdings AG (Switzerland)
- Insulet Corporation (US)
- Tandem Diabetes Care (US)
- B. Braun Melsungen AG (Germany)
- LifeScan, Inc. (US)
- Tidepool (US)
- AgaMatrix (US)
- Glooko, Inc. (US)
- DarioHealth Corporation (Israel)
- One Drop (US)
- Dottili (Finland)
- Ypsomed Holding AG (Switzerland)
- ARKRAY (Japan)
- ACON Laboratories, Inc. (US)
- Care Innovations, LLC (US)
- Health2Sync (Taiwan)
- Emperra GmbH E-Health Technologies (Germany)
- Azumio (US)
- Decide Clinical Software GmbH (Austria)
- Pendiq GmbH (Germany)
- BeatO (India)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size Value in 2026 (Value) | USD 7.78 Billion |
| Revenue Forecast in 2031 (Value) | USD 12.53 Billion |
| Growth Rate | 10.0% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD MillionN/Billion), Volume (Thousand Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | By Product & Service: Devices, Apps, Data Management Software & Platforms and Services, By Device Type: Wearable Devices, Handheld Devices, By End User: Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, Academic & Research Institutes |
| Country Covered | Germany, France, UK, Italy, Spain, and Rest of Europe |
| Parent & Related Segment Reports |
Digital Diabetes Management Market US Digital Diabetes Management Market |
WHAT IS IN IT FOR YOU: EUROPE DIGITAL DIABETES MANAGEMENT MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Comparative analysis of digital diabetes solutions including CGM systems, connected blood glucose meters, insulin pumps, mobile health apps, and AI-enabled data platforms, with assessment of standalone vs integrated ecosystems across Europe | Evaluation of data accuracy, interoperability, user experience, clinical decision support, and real-world outcome impact to support optimized diabetes care pathways in European healthcare systems |
| Company Information | Detailed profiles of leading global and European digital diabetes players covering product portfolios, software capabilities, regulatory approvals, reimbursement status, partnerships, and recent developments across key European countries | Competitive benchmarking of players based on technology maturity, reimbursement access, ecosystem strength, and innovation focus, enabling strategic positioning and partner selection |
| Geographic Analysis | In-depth regional assessment of the Europe digital diabetes management market covering Germany, the UK, France, Italy, Spain, Nordics, and other key markets | Country-level market sizing, CAGR forecasts, reimbursement landscape analysis, digital adoption trends, and policy impact assessment to guide market entry and expansion strategies |
RECENT DEVELOPMENTS
- April 2022 : Dexcom launched Dexcom ONE device worldwide.
- October 2022 : Abbott Laboratories launched the Freestyle Libre 3 CGM device worldwide.
- October 2021 : LifeScan, Inc. (US) launched OneTouch Solutions. This is a holistic digital health offering linking people with diabetes to solutions and support from proven experts.
- September 2020 : Roche Diagnostics (Switzerland) launched a remote patient monitoring solution, which is a new element of the RocheDiabetes Care Platform and uses its pattern detection feature.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.2
RESTRAINTS
4.2.3
OPPORTUNITIES
4.2.4
CHALLENGES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN EUROPE DIGITAL DIABETES MANAGEMENT INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.2
AVERAGE SELLING PRICE TREND OF EUROPE DIGITAL DIABETES MANAGEMENT, BY TYPE, 2023–2025
5.7
TRADE ANALYSIS
5.7.1
IMPORT SCENARIO (902780)
5.7.2
EXPORT SCENARIO (902780)
5.8
KEY CONFERENCES AND EVENTS, 2025–2026
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
CASE STUDY ANALYSIS
5.12
IMPACT OF 2025 US TARIFF ON EUROPE DIGITAL DIABETES MANAGEMENT MARKET
5.12.1
INTRODUCTION
5.12.2
KEY TARIFF RATES
5.12.4
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES
5.12.4.1
GERMANY
5.12.4.2
UK
5.12.4.3
FRANCE
5.12.4.4
ITALY
5.12.4.5
SPAIN
5.12.4.6
REST OF EUROPE
5.12.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.5
FUTURE APPLICATIONS
6.6
IMPACT OF AI/GEN AI ON EUROPE DIGITAL DIABETES MANAGEMENT MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN EUROPE DIGITAL DIABETES MANAGEMENT PROCESSING
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN EUROPE DIGITAL DIABETES MANAGEMENT MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE DIGITAL DIABETES MANAGEMENT MARKET
7
REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE (USD MILLION AND VOLUME IN THOUSAND UNITS 2024-2031)
9.1
INTRODUCTION
9.2
DEVICES
9.2.1
SMART GLUCOSE METERS
9.2.2
CONTINUOUS GLUCOSE MONITORING SYSTEMS
9.2.3
SMART INSULIN PENS
9.2.4
SMART INSULIN PUMPS/CLOSED LOOP SYSTEMS & SMART INSULIN PATCHES
9.3
DIGITAL DIABETES MANAGEMENT APPS
9.3.1
DIABETES & BLOOD GLUCOSE TRACKING APPS
9.3.2
WEIGHT & DIET MANAGEMENT APPS
9.4
DATA MANAGEMENT SOFTWARE AND PLATFORMS
9.5
SERVICES
10
EUROPE DIGITAL DIABETES MANAGEMENT MARKET, BY DEVICE TYPE (USD MILLION 2024-2031)
10.1
INTRODUCTION
10.2
WEARABLE DEVICES
10.3
HANDHELD DEVICES
11
EUROPE DIGITAL DIABETES MANAGEMENT MARKET, BY END USER (USD MILLION 2024-2031)
11.1
INTRODUCTION
11.2
SELF/HOMECARE HEALTHCARE
11.3
HOSPITALS & SPECIALTY DIABETES CLINICS
11.4
ACADEMIC & RESEARCH INSTITUTES
12
EUROPE DIGITAL DIABETES MANAGEMENT MARKET, BY COUNTRY (USD MILLION 2024-2031)
12.1
GERMANY
12.2
UK
12.3
FRANCE
12.4
ITALY
12.5
SPAIN
12.6
REST OF EUROPE
13
COMPETITIVE LANDSCAPE
13.1
INTRODUCTION
13.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
13.3
REVENUE ANALYSIS
13.4
MARKET SHARE ANALYSIS
13.5
PRODUCT COMPARISON
13.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
13.6.1
STARS
13.6.2
EMERGING LEADERS
13.6.3
PERVASIVE PLAYERS
13.6.4
PARTICIPANTS
13.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
13.6.5.1
COMPANY FOOTPRINT
13.6.5.2
COUNTRY FOOTPRINT
13.6.5.3
PRODUCT & SERVICE FOOTPRINT
13.6.5.4
DEVICE TYPE FOOTPRINT
13.6.5.5
END-USER FOOTPRINT
13.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
13.7.1
PROGRESSIVE COMPANIES
13.7.2
RESPONSIVE COMPANIES
13.7.3
DYNAMIC COMPANIES
13.7.4
STARTING BLOCKS
13.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
13.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
13.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
13.8
COMPANY VALUATION AND FINANCIAL METRICS
13.9
COMPETITIVE SCENARIO
13.9.1
PRODUCT LAUNCHES
13.9.2
DEALS
13.9.3
EXPANSIONS
14
COMPANY PROFILES
14.1
KEY PLAYERS
14.1.1
MEDTRONIC PLC
14.1.2
F. HOFFMANN-LA ROCHE
14.1.3
ABBOTT LABORATORIES
14.1.4
B. BRAUN MELSUNGEN AG
14.1.5
DEXCOM, INC.
14.1.6
INSULET CORPORATION
14.1.7
TANDEM DIABETES CARE
14.1.8
ASCENSIA DIABETES CARE HOLDINGS AG
14.1.9
LIFESCAN, INC.
14.1.10
TIDEPOOL
14.1.11
AGAMATRIX
14.1.12
GLOOKO, INC.
14.1.13
DARIOHEALTH CORPORATION
14.1.14
ONE DROP
14.1.15
YPSOMED HOLDING AG
14.2
OTHER PLAYERS
14.2.1
ARKRAY
14.2.2
ACON LABORATORIES, INC.
14.2.3
CARE INNOVATIONS, LLC
14.2.4
HEALTH2SYNC
14.2.5
EMPERRA GMBH E-HEALTH TECHNOLOGIES
14.2.6
PENDIQ GMBH
14.2.7
BEATO
14.2.8
AZUMIO
14.2.9
DECIDE CLINICAL SOFTWARE GMBH
14.2.10
DOTTLI
15
RESEARCH METHODOLOGY
15.1
RESEARCH DATA
15.1.1
SECONDARY DATA
15.1.1.1
KEY DATA FROM SECONDARY SOURCES
15.1.2
PRIMARY DATA
15.1.2.1
KEY DATA FROM PRIMARY SOURCES
15.1.2.2
KEY PRIMARY PARTICIPANTS
15.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
15.1.2.4
KEY INDUSTRY INSIGHTS
15.2
MARKET SIZE ESTIMATION
15.2.1
BOTTOM-UP APPROACH
15.2.2
TOP-DOWN APPROACH
15.3
MARKET FORECAST APPROACH
15.3.1
SUPPLY SIDE
15.3.2
DEMAND SIDE
15.4
DATA TRIANGULATION
15.5
FACTOR ANALYSIS
15.6
RESEARCH ASSUMPTIONS
15.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
16
APPENDIX
16.1
DISCUSSION GUIDE
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3
CUSTOMIZATION OPTIONS
16.4
RELATED REPORTS
16.5
AUTHOR DETAILS
Methodology
The study involved four major activities in estimating the current size of the Europe Digital Diabetes Management Market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary sources referred to for this research study include financial statements of companies offering Digital Diabetes Management and information from various trade, business, and professional associations. The secondary data was collected and analyzed to arrive at the overall size of the Europe Digital Diabetes Management Market, which was validated by primary respondents.
Primary Research
Extensive primary research was conducted after obtaining information regarding the Europe Digital Diabetes Management Market scenario through secondary research. Several primary interviews were conducted with market experts from both, the demand and supply sides across Europe. Primary data was collected through questionnaires, emails, and telephonic interview. The primary sources from the supply side included various industry experts, such as Chief X Officers (CXOs), Vice Presidents (VPs), Directors, from business development, marketing, product development/innovation teams, and related key executives from Digital Diabetes Management manufacturers; distributors; and key opinion leaders.
Primary interviews were conducted to gather insights such as market statistics, data of revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to technology, application, vertical, and region. Stakeholders from the demand side, customer/end users who are using Digital Diabetes Management were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage of Digital Diabetes Management and future outlook of their business which will affect the overall market.
Market Size Estimation
The research methodology used to estimate the size of the Europe Digital Diabetes Management Market includes the following details.
The market sizing of the market was undertaken from the global side.
Country level Analysis: The size of the Europe Digital Diabetes Management Market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products and services in the overall Europe Digital Diabetes Management Market was obtained from secondary data and validated by primary participants to arrive at the total Europe Digital Diabetes Management Market. Primary participants further validated the numbers.
Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall Europe Digital Diabetes Management Market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.
Data Triangulation
After arriving at the overall size from the market size estimation process explained above, the total market was split into several segments and subsegments. The data triangulation and market breakdown procedures explained below were implemented, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for various market segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size was validated using both the top-down and bottom-up approaches.
Market Definition
Digital diabetes management refers to electronic medical solutions used for remote monitoring, analysis and management of patients with diabetes. Diabetes is a metabolic disorder that leads to elevated blood sugar levels in the body. Digital diabetes management involves the use of software-based applications, platforms and devices, such as smart glucose meters, insulin pens, sensors, closed-loop systems and insulin patches.
These systems are used to manage blood glucose, pressure and cholesterol levels and effectively track and maintain the record of the patients. They also aid in improving healthcare processes, delay or prevent diabetes complications and minimize medical costs for the patients. As a result, they are widely used across at-home and self-care facilities, hospitals, clinics and research institutes.
Key Stakeholders
- Senior Management
- End Users
- Diabetes Care Providers
- Finance/Procurement Department
Report Objectives
- To define, describe, analyze, and forecast the Europe Digital Diabetes Management Market by product, type, end user, and region
- To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To strategically profile key players in the Europe Digital Diabetes Management Market and comprehensively analyze their core competencies
- To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, agreements, and other developments of leading players in the Europe Digital Diabetes Management Market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe Digital Diabetes Management Market into the Netherlands, Austria, Belgium, and others
- Further breakdown of the Rest of Asia Pacific Europe Digital Diabetes Management Market into Singapore, Malaysia, and others
Company Information
- Detailed analysis and profiling of additional market players
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Digital Diabetes Management Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Europe Digital Diabetes Management Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
